Scientific Programme

Saturday, 16. July 2016

Plenary Session
08:30 - 09:45  Session Room 12

OS, Opening Session

Chairs:
Valerie Mizrahi (UCT)

Welcome Address  08:30
Dr. Aaron Motsoaledi (Minister of Health, South Africa)

Why TB 2016? Why now?  08:45
Jens Lundgren (University of Copenhagen)

Joining the TB and HIV Global Communities  09:00
José Luis Castro (International Union Against Tuberculosis and Lung Disease)

Universal Health Care: The Key to Ending TB by 2030?  09:15
Eric Goosby (UN Special Envoy on TB)

The Role of Communities in Responding to the Global TB Epidemics  09:30
Thokozile Phiri (Facilitators of Community Transformation)

PS1, Plenary Session

Chairs:
Zelalem Temesgen (Mayo Clinic, Minnesota, United States)
Anneke Hesseling (Desmond Tutu TB Centre)

Understanding the biology of tuberculosis and its impact on drug discovery and development  10:00
Clifton Barry (NIAID)

Critical questions and new approaches in TB vaccinology  10:20
Willem Hanekom (The Gates Foundation)

How latent is latent TB?  10:40
Robert Wilkinson (Crick Institute & UCT)

Using Rights to Health and Scientific Progress to Advance TB Research and Access  11:00
Mike Frick (Treatment Action Group, New York, United States)

Questions and Answers  11:20
Scientific Programme

BS1, Breakout Session 1: New Approaches in Prevention Research

Chairs:
Gilla Kaplan (Bill & Melinda Gates Foundation)
Diane Havlir (UCSF)

Towards a correlate of protective immunity to TB  11:45
David Russell (Cornell University)

Potential indications and target populations for a new TB vaccine  12:00
Mark Hatherill (SATVI, UCT)

Drivers of Tuberculosis Transmission  12:15
Robin Wood (Desmond Tutu HIV Centre, UCT)

Serial Quantiferon testing predicts disease risk among infants in high-transmission settings  12:30
Jason Andrews (Stanford University School of Medicine)

Breakout Session 2: Ending TB Drug Shortages

Chairs:
Sharonann Lynch (Doctors Without Borders)
Lucica Ditiu (Stop TB)

Supply challenges in endemic settings  11:45
Welile Sikhondze (NTCP Swaziland)

Supply challenges in the US  12:00
Kenyon Farrow (Treatment Action Group)

The impact of supply shortages on people living with TB  12:15
Yuliia Kalancha (Aids Healthcare Foundation - Ukraine (AHF Ukraine))

Questions and Answers  12:30

TB and HIV Co-infection: From Immune-pathogenesis to Integrated Care

Perceived barriers and facilitators of isoniazid preventive therapy among HIV-infected pregnant women in South Africa
Hae-Young Kim (Johns Hopkins Bloomberg School of Public Health, Maryland, United States)

HIV prevalence, TB treatment outcomes and determinants of default in adolescents and young adults treated for TB in Cape Town
Pancho Mulongeni (The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa)
Scientific Programme

Outcomes of efavirenz- and non-efavirenz containing ART in HIV-positive patients co-infected with tuberculosis in Eastern Europe, Western Europe and Latin America
Brenda Crabtree-Ramírez (Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico)

Self-reported adherence to antiretroviral therapy predicts subsequent retention in care for extensively drug-resistant tuberculosis (XDR-TB) HIV co-infected patients on treatment in KwaZulu-Natal, South Africa
Max O'Donnell (Columbia University, NY, United States)

Plasma cytokine predictors of TB recurrence in HIV-infected individuals on ART in Durban, South Africa
Aida Sivro (Centre for the AIDS Programme of Research in South Africa (CAPRISA), KwaZulu-Natal, South Africa)

Provider-initiated HIV counselling and testing for patients with presumptive tuberculosis in Mandalay General Hospital, Myanmar, 2014-2015
Nang Thu Thu Kyaw (International Union against Tuberculosis and Lung Disease, Mandalay, Myanmar)

Mortality and associated factors in ART-naive HIV-infected children with a suspicion of tuberculosis
Olivier Marcy (Universite de Bordeaux, France)

Extensively drug resistant tuberculosis and HIV co-infection in KwaZulu-Natal, South Africa (the PROX study): treatment outcomes and molecular epidemiology
Kay Yeungling (Columbia University, United States)

TB diagnosis with combined point-of-care tests in HIV+ patients in Mozambique
Haswel Jere (DREAM Program, Malawi)

Challenges to the integration of HIV and M/XDR-TB services in South Africa: a qualitative study of frontline health providers
Amrita Daftary (McGill University, QC, Canada)

Intensified tuberculosis case-finding among people living with HIV under integrated HIV care program in upper Myanmar, 2015
Khine Wut Yee Kyaw (International Union against Tuberculosis and Lung Disease, Mandalay, Myanmar)

The evolution of Mycobacterium tuberculosis in HIV co-infected individuals in an HIV/TB endemic setting
Anastasia Koch (University of Cape Town, Western Cape, South Africa)

High-dose rifampicin tuberculosis treatment regimen to reduce 12-month mortality of TB/HIV co-infected patients: The RAFA trial results
Corinne Simone Merle (WHO, Switzerland)

Implementation Science: Delivering Interventions to TB and its Co-morbidities (Diabetes, Alcohol, Malnutrition, Tobacco)

Opportunity to reduce pre-diagnosis attrition among patients with presumptive MDR-TB in Bhopal district, India: an operational research
Hemant Deepak Shewade (International Union against Tuberculosis and Lung Disease, None Selected, India)
Scientific Programme

“Finding” TB in India via active pharmacy engagement: early results from the IC-IMPACTS study
Amrita Daftary (McGill University, QC, Canada)

Use of GeneXpert and household-based TB screening for detecting MDR TB in HIV-positive clients in two communities in Lusaka, Zambia during HPTN 071 (PopART study)
Ephraim Sakala (Zambart, Lusaka, Zambia)

Intervention for patients interrupting rifampicin-resistant tuberculosis treatment for greater than two weeks: a descriptive analysis from Khayelitsha, South Africa
Erika Mohr (Medecins Sans Frontieres, Western Cape, South Africa)

Cost-effectiveness of triage testing for facility-based systematic screening of tuberculosis among Ugandan adults
Matthew Murray (Johns Hopkins Bloomberg School of Public Health, Maryland, United States)

Timing of contact tracing of household members of tuberculosis cases for optimal yield and resource allocation
Laura Podewils (Centers for Disease Control and Prevention, Georgia, United States)

Access to second-line treatment for children diagnosed with rifampicin-resistant tuberculosis in South Africa: a national retrospective cohort study
Lindy Dickson-Hall (University of Cape Town, Western Cape, South Africa)

Screening for active TB in a diabetes mellitus clinic in Soweto, South Africa
Jonathan Golub (Johns Hopkins School of Medicine, Maryland, United States)

Improving TB treatment outcomes in Matlosana and Ventersdorp sub-districts, Dr Kenneth Kaunda District, 2009 to 2014
Georgina Wessie (University Research Co., LLC South Africa, South Africa)

Self-administered treatment for the continuation phase of rifampicin-resistant tuberculosis treatment: feasibility and impact on patient outcomes in Khayelitsha, South Africa
Erika Mohr (Medecins Sans Frontieres, Western Cape, South Africa)

Universal Access to TB Care (UATBC): information technology platform to drive scale up in private sector engagement
Rishabh Chopra (PATH, India)

Prevalence of and risk factors for diabetes mellitus among pulmonary tuberculosis patients in Pune, India
Jonathan Golub (Johns Hopkins School of Medicine, Maryland, United States)

“Keeping-up with the DOTS”: patients’ perspectives of a financial incentive intervention to improve tuberculosis care: a qualitative study
Kingsley Nnanna Ukwaja (Department of Medicine, Federal Teaching Hospital Abakaliki, Nigeria)

Poster Exhibition
Poster Room

Measuring the TB Epidemic: What is the best Method? (Prevalence Surveys and Programmatic Implications)

Autopsy prevalence of TB and other infections in adults with advanced HIV enrolled in out-patient care in South Africa
Aaron S Karat (London School of Hygiene and Tropical Medicine, United Kingdom)
Scientific Programme

Prevalence of latent TB infection among adults in endemic regions screened for a phase 2b, double-blind, randomized, placebo-controlled study to evaluate GSK candidate vaccine M72/AS01E (NCT01755598)
Gretta Blatner (Aeras, MD, United States)

Poster Exhibition
13:00 - 14:00
Poster Room

Advances in Understanding the Basic Biology of TB

Metabolomics - identifying small tuberculosis biomarkers with big implications
Ilse Du Preez (North-West University, Northwest Province, South Africa)

Global transcriptional profiling elucidates significant up-regulation of host cytokines, chemokines and chemokine receptors by heparin binding hemagglutinin adhesin in BALB/c mice lungs
Sumira Kuvar (University of KwaZulu-Natal, KwaZulu-Natal, South Africa)

Prevalence of inhA and KatG mutations and associated treatment outcomes among persons with multidrug resistant tuberculosis in Khayelitsha, South Africa
Erika Mohr (Medecins Sans Frontieres, Western Cape, South Africa)

Unvisited players of eicosanoid pathway in Mycobacterium tuberculosis infection: cysteinyl leukotrienes
Mumin Ozturk (University of Cape Town, South Africa)

Whole transcriptome analysis to elucidate the role of M. tuberculosis curli pili (MTP) on host gene regulation in a pulmonary epithelial cell model
Mlungisi Dlamini (University of KwaZulu-Natal (NRMSM), KwaZulu-Natal, South Africa)

Growth of Mycobacterium tuberculosis in dead macrophages drives a host cell death cascade
Deeqa Mahamed (K-RITH, KZN, South Africa)

Investigating the cost of rifampicin-resistance in mycobacteria
Bevika Sewgoolam (University of Cape Town, Western Cape, South Africa)

Oral Presentation Posters: MDR and XDR: diagnosis and impact

Higher cost of implementing Xpert MTB/RIF in peripheral settings in Uganda: implications for cost-effectiveness
David Dowdy (Johns Hopkins Bloomberg School of Public Health, MD, United States)

Large-scale expansion of drug-resistant tuberculosis case-finding in Mumbai via private provider engagement
Rishabh Chopra (PATH, India)

Development of a reporter mycobacteriophage assay to detect emergent drug resistant MTB subpopulations
Lorenzo Uccellini (Columbia University, NY, United States)
**Significant and sustained decline in extensively and multiple drug resistant tuberculosis (XDR/MDR TB) from 2005-2014 in Tugela Ferry, KwaZulu-Natal South Africa**

Gerald Friedland (Yale School of Medicine, Connecticut, United States)

**Oral Presentation Posters: Prevention of HIV-associated TB**

- **Effectiveness and feasibility of implementation of isoniazid preventive therapy for HIV infected children attending ART Clinics in India**
  P.K Bhavani (National Institute for Research in Tuberculosis, Tamilnadu, India)

- **Effectiveness of isoniazid preventive therapy in reducing incidence of tuberculosis among PLHIV in programme settings in India**
  Chandrasekaran Padmapriyadarsini (National Institute for Research in Tuberculosis, Tamilnadu, India)

- **HIV viral load as an independent risk factor for tuberculosis in South Africa**
  Lukas Fenner (Institute of Social and Preventive Medicine, University of Bern, Switzerland)

- **Detection and characterisation of Mycobacterium tuberculosis-specific CD4+ T cells using MHC class II tetramers in latent TB infection**
  Natalie Strickland (IDM, University of Cape Town, Western Cape, South Africa)

**Parallel Session 1 (Abstracts): MDR and XDR: diagnosis and impact**

*Chairs:*
Gavin Churchyard (The Aurum Institute)
Neil Martinson (Perinatal HIV Research Unit)

- **Higher cost of implementing Xpert MTB/RIF in peripheral settings in Uganda: implications for cost-effectiveness**
  David Dowdy (Johns Hopkins Bloomberg School of Public Health, MD, United States)

- **Large-scale expansion of drug-resistant tuberculosis case-finding in Mumbai via private provider engagement**
  Rishabh Chopra (PATH, India)

- **Development of a reporter mycobacteriophage assay to detect emergent drug resistant MTB subpopulations**
  Lorenzo Uccellini (Columbia University, NY, United States)

- **Significant and sustained decline in extensively and multiple drug resistant tuberculosis (XDR/MDR TB) from 2005-2014 in Tugela Ferry, KwaZulu-Natal South Africa**
  Gerald Friedland (Yale School of Medicine, Connecticut, United States)
Parallel Session
14:00 - 15:00
Session Room 10

Parallel Session 2 (Abstracts): Prevention of HIV-associated TB

Chairs:
Jason Andrews (Stanford University School of Medicine)
Alison Grant (LSHTM)

Effectiveness and feasibility of implementation of isoniazid preventive therapy for HIV infected children attending ART Clinics in India
P.K Bhavani (National Institute for Research in Tuberculosis, Tamilnadu, India) 14:00

Effectiveness of isoniazid preventive therapy in reducing incidence of tuberculosis among PLHIV in programme settings in India
Chandrasekaran Padmapriyadarsini (National Institute for Research in Tuberculosis, Tamilnadu, India) 14:15

HIV viral load as an independent risk factor for tuberculosis in South Africa
Lukas Fenner (Institute of Social and Preventive Medicine, University of Bern, Switzerland) 14:30

Detection and characterisation of Mycobacterium tuberculosis-specific CD4+ T cells using MHC class II tetramers in latent TB infection
Natalie Strickland (IDM, University of Cape Town, Western Cape, South Africa) 14:45

Plenary Session
15:15 - 16:30
Session Room 12

BS3, Breakout Session 3: Understanding and Intervening in Progression from Infection to Disease

Chairs:
Richard Chaisson (Johns Hopkins)
Robert Wilkinson (Crick Institute & UCT)

Advantage of rifamycin containing regimens over isoniazid in high transmission settings: what is the evidence?
Tom Sumner (London School of Hygiene & Tropical Medicine) 15:15

Advances in LTBI regimens: an update on ongoing clinical trials
Tim Sterling (Vanderbilt Tuberculosis Centre) 15:30

Are there lessons for TB from long-acting ART?
Susan Swindells (University of Nebraska Medical Center, Nebraska, United States) 15:45

High-dose rifampicin tuberculosis treatment regimen to reduce 12-month mortality of TB/HIV co-infected patients: The RAFA trial results
Corinne Simone Merle (WHO, Switzerland) 16:00

Questions and Answers 16:15
Scientific Programme

Plenary Session
15:15 - 16:30
Session Room 10

Breakout Session 4: Transitioning from Research and Development to Access for Children with TB

Chairs:
Eliud Wandwalo (Global Fund)
Carol Dukes Hamilton (Duke University & fhi360)

15:15
Filling research gaps for children with TB
Jennifer Furin (Harvard Medical School, Massachusetts, United States)

15:30
Developing and registering paediatric formulations for TB
Vijay Agarwal (Macleods Pharma)

15:45
Programme considerations for integrating new tools
John Ditekemena (EGPAF)

Plenary Session
16:45 - 18:00
Session Room 12

BS5, Breakout Session 5: TB Drug Discovery and Development - Where are we Heading?

Chairs:
Clifton Barry (NIAID)
Luis Soto-Ramirez (Instituto Nacional)

16:45
Opportunities and challenges in TB drug discovery: lessons from the benzothiazinones
Stewart Cole (EPFL)

17:00
Lesion penetration as a critical determinant of TB drug efficacy
Rada Savic (UCSF)

17:15
Prospects for antimicrobial drug re-purposing
Florian Von Groote-Bidlingmaier (TASK Applied Science)

17:30
Novel pathways for host-targeted therapy
Jerrold Ellner (Boston University)

17:45
Questions and Answers

Plenary Session
16:45 - 18:00
Session Room 10

Breakout Session 6: Aligning and Achieving Targets for HIV/AIDS and TB Control

Chairs:
Joanne Carter (RESULTS)
Michael Kimerling (KNCV Foundation)

16:45
90-90-90 targets for TB
Paula Fujiwara (TB Union)
## Scientific Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00</td>
<td><strong>Aligning HIV and TB targets in Eastern Europe and Central Asia</strong></td>
<td>Michel Kazatchkine (UN Secretary-General’s Special Envoy on HIV/AIDS in Eastern Europe and Central Asia)</td>
</tr>
<tr>
<td>17:15</td>
<td><strong>Vital gaps in reaching TB targets</strong></td>
<td>Shannon Hader (US CDC)</td>
</tr>
<tr>
<td>17:30</td>
<td><strong>Innovative financing in the fight to end TB</strong></td>
<td>Robert Matiru (Unitaid)</td>
</tr>
<tr>
<td>17:45</td>
<td><strong>Questions and Answers</strong></td>
<td></td>
</tr>
</tbody>
</table>
PS2, Plenary Session

Chairs:
Ann Ginsberg (Aeras)
Eric Goosby (UN Special Envoy on TB)

08:30  Evolution and spread of drug resistance - a slow moving process with great public health impact
Sebastién Gagneux (Swiss TBH)

08:50  Diagnosis of HIV-associated TB: Translating new knowledge and tools to maximise clinical impact
Robin Wood (Desmond Tutu HIV Centre, UCT)

09:10  Better evidence, better policy
Yogan Pillay (National Department of Health)

09:30  Leaving No One Behind - Key Populations in TB
Lucica Ditiu (Stop TB)

09:50  Questions and Answers

Parallel Session 3 (Abstracts): Transmission and Diagnosis

Chairs:
Stewart Cole (EPFL)
Anton Pozniak (Chelsea & Westminster NHS)

10:30  Deterministic linkage to evaluate the burden of recurrent TB disease in Cape Town, South Africa
Sabine Hermans (Desmond Tutu HIV Centre, Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa)

10:45  Mycobacterium tuberculosis molecular screening assay with sensitivity equivalent to culture
Sally McFall (Northwestern University, Illinois, United States)

11:00  Diagnostic accuracy of Xpert®MTB/Rif, experience at district hospital of Buenos Aires for tuberculosis diagnosis
Omar Sued (Hospital J. A. Fernandez, Buenos Aires, Argentina)

11:15  Development of a multi-analyte panel for non-invasive pharmacokinetic monitoring of second-line anti-tuberculosis drugs in small hair samples
John Metcalfe (University of California San Francisco (UCSF), United States)
Parallel Session
10:30 - 11:30 Session Room 10

Parallel Session 4 (Abstracts): Paediatric MDR TB and Clinical Epidemiology

Chairs:
Paula Fujiwara (TB Union)
Kevin Cain (KEMRI)

- **Diabetes and tuberculosis in Korean men and women: impact on tuberculosis incidence, recurrence and mortality**
  Jonathan Golub (Johns Hopkins School of Medicine, Maryland, United States) 10:30
- **Spatio-temporal clustering of drug-resistant tuberculosis in KwaZulu-Natal, South Africa 2004-2010**
  Allison Wolf (Columbia University, New York, United States) 10:45
- **Safety and tolerability of levofloxacin in HIV-infected and -uninfected children treated for multidrug-resistant tuberculosis**
  Anthony Garcia-Prats (Stellenbosch University, South Africa) 11:00
- **Treatment of multidrug-resistant tuberculosis (MDR-TB) in children and adolescents with a 9-month regimen in Africa**
  Bassirou Souleymane (Action Damien Niger, Niger) 11:15

Plenary Session
11:45 - 13:00 Session Room 12

BS7, Breakout Session 7: MDR/XDR TB

Chairs:
Daria Podlekareva (Nordsjaellands Hospital, Hilleroed and Rigshospitalet)
Robin Wood (Desmond Tutu HIV Centre, UCT)

- **Evolution of Drug Resistance in KwaZulu-Natal and implications for TB control**
  Alex Pym (K-RITH) 11:45
- **Advances in improving treatment outcomes for MDR/XDR TB**
  Gunar Günther (University of Namibia, School of Medicine) 12:00
- **Diagnostic advances in MDR/XDR TB and their impact on clinical outcomes**
  Susan Dorman (Johns Hopkins University School of Medicine) 12:15
- **Decentralization of MDR-TB: a case study from South Africa**
  Virginia de Azavedo (City of Capetown) 12:30

Questions and Answers 12:45
Scientific Programme

Plenary Session
11:45 - 13:00
Session Room 10

Breakout Session 8: Human Rights and TB Research: Realizing the Right to Scientific Progress for TB

Chairs:
Erica Lessem (TAG)
Diana Elizabeth Weil (WHO)

11:45 Returning to Durban: Science, Human Rights and Activism at the Centre of the TB/HIV epidemics
Eric Goosby (UN Special Envoy on TB)

12:00 Developing a Rights-Based Approach to TB: Concepts, Case Law and Legislation
Brian Citro (International Human Rights Clinic, University of Chicago Law School)

12:15 Incorporating community voices into TB science and programme
Kethelelie Angami (Nagaland Users Network)

12:30 Using the law to safeguard rights of TB patients
Allan Maleche (Kenya Legal and Ethical Issues Network)

12:45 Questions and Answers

Poster Exhibition
13:00 - 14:00
Poster Room

Understanding TB Infectiousness and Transmission

Global transcriptome analysis reveals up-regulation of host cytokine genes, and cytokine and chemokine receptor binding in BALB/c mice by Mycobacterium tuberculosis curli pili (MTP)
Georgina Nyawo (University of KwaZulu-Natal, KwaZulu-Natal, South Africa)

Comparison of indoor contact time in Zambia and South Africa suggests targeting of interventions to reduce Mycobacterium tuberculosis transmission should be informed by local data
Nicky McCreesh (London School of Hygiene and Tropical Medicine, United Kingdom)

A5300/I2003: feasibility of identifying, recruiting and characterizing adult MDR TB index cases and their adult and child household contacts on four continents
Susan Swindells (University of Nebraska Medical Center, Nebraska, United States)

Extensively drug-resistant M. tuberculosis strains of the F15/LAM4/KZN genotype exhibit enhanced proinflammatory cytokine induction in THP-1 macrophages
Charissa Camille Naidoo (Stellenbosch University, South Africa)

Poster Exhibition
13:00 - 14:00
Poster Room

New Advances in Clinical Research including Pediatric TB
Scientific Programme

**IMPAACT P1113/aeras C-015-404: Phase I/II study of H4:IC31 in BCG-primed infants**
Avi Violari (Perinatal HIV Research Unit, Chris Hani Baragwaneth Hospital, University of the Witwatersrand, Soweto, South Africa)

**Serial plasma cytokine levels in childhood tuberculosis: potential biomarkers for predicting therapeutic outcome**
Aparna Mukherjee (All India Institute of Medical Sciences (AIIMS), Delhi, India)

**Initial management of MDR-TB in HIV co-infected patients in Eastern Europe: results from the TB:HIV study**
Anne Marie Werlinrud Efsen (Copenhagen Centre for Health and Infectious Disease Research (CHIP), Rigshospitalet, University of Copenhagen, Denmark)

**Updated preliminary results of treatment of multidrug-resistant tuberculosis (MDR-TB) with a 9-month regimen in francophone Africa**
Valerie Schwoebel (International Union Against Tuberculosis & Lung Disease, Not Applicable, France)

**Poster Exhibition**
13:00 - 14:00
Poster Room

**New Tools, R&D Drugs, Diagnostics and Vaccines**

**Use of QuantiFERON ®-TB Gold assay in clinical trials: effect of immediate incubation and temperature variations during transportation on assay outcomes**
Maureen Lambrick (Aeras Africa, South Africa)

**Resolution of discordant rifampicin genotypic and phenotypic drug susceptibility testing in TB/HIV co-infected patients**
Bianca Sansom (National Institute for Communicable Diseases, Gauteng, South Africa)

**Prevalence of bedaquiline resistance-conferring mutations in drug resistant tuberculosis patients in South Africa**
Lavania Joseph (National Institute for Communicable Diseases, Gauteng, South Africa)

**Development of an in-house single step loop mediated isothermal amplification assay for the detection of Mycobacterium tuberculosis complex in sputum samples from moroccan patients**
El Mehdi Bentaleb (Moroccan Foundation for Advanced Science, Innovation and Research (MAScIR), Rabat, Morocco)

**Affordability of comprehensive MDR-TB treatment with novel regimens, at current prices versus estimated competitive generic prices**
Dzintars Gotham (Imperial College London, United Kingdom)

**Laboratory detection of rifampicin low level resistance in Mycobacterium tuberculosis**
Nomonde Ritta Mvelase (University of KwaZulu-Natal&National Health Laboratory Service, KwaZulu-Natal, South Africa)

**Evaluation of the fluorotype MTB assay for detection of Mycobacterium tuberculosis complex DNA in fineneedle aspiration biopsy (FNAB) specimens**
Sharlene Govender (Nelson Mandela Metropolitan University, Eastern Cape, South Africa)

**DNA extracted from used Xpert MTB/RIF cartridges can be used for second-line drug susceptibility testing**
Rouxjeane Venter (Stellenbosch University, Western Cape, South Africa)
Identification of biomarkers predictive of early stage tuberculosis infection
Eustache Paramithiotis (Caprion Biosciences Inc, Quebec, Canada)

Effect of sputum quality and volume on the yield of bacteriologically confirmed TB by Xpert and smear microscopy among people living with HIV in Botswana
Onani Zimba (CDC Botswana, Botswana)

Early morning urine collection to improve urinary LAM lateral flow assay sensitivity in hospitalised patients with HIV-TB co-infection
Phindile Gina (Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, University of Cape Town, Western Cape, South Africa)

Evaluation of Anyplex II™ MTB/MDR-TB for rapid detection of multidrug resistant tuberculosis (MDR-TB) on clinical sediments
Tsireledzo Raidani (Sefako Makgatho Health Science University, South Africa)

Comparison between Bedaquiline minimum inhibitory concentrations using the agar proportion method and the Sensititre broth microdilution method
Tracy Arendse (National Institute for Communicable Diseases, Gauteng, South Africa)

Decreased sensitivity and increased indeterminate rates of GenoType MTBDRplus (v2.0) are associated with use of inappropriate PCR ramp rate: implications for routine diagnostic laboratories
Brigitta Derendinger (Stellenbosch University, Western Cape, South Africa)

Community Engagement and Innovations

Lessons learned with the implementation of household TB screening, diagnosis and initiation of TB treatment in South Africa
Francionette Esau (University of Stellenbosch, Western Cape, South Africa)

Building the capacity of local language media to report on TB
Amy Israel (Lilly MDR-TB Partnership and Eli Lilly & Co. Ltd., Switzerland)

Impact of directly-observed treatment support offered by local NGO in Mahikeng Sub-district, Ngaka Modiri Molema District, North West Province, 2013 - 2014
Georgina Wessie (University Research Co., LLC South Africa, South Africa)

Improving the quality of data to improve TB treatment outcomes in Sub-district A, Nelson Mandela Bay Health District, South Africa
Liziwe Canzibe (University Research Co., LLC South Africa, South Africa)

Tackling TB in early childhood development centres in Ethekwini Metro, KwaZulu Natal, South Africa
Fikile Dlongolo (University Research Co., LLC South Africa, South Africa)

Introduction of TB screening services in 17 correctional setting through a non-governmental organisation
Claire Rademeyer (Footballers 4 Life, South Africa)

Active case finding revealing the hidden face of tuberculosis within 80 slum areas in Oyo State of Nigeria
Samuel Okunoye Okewoye (MATHAMAN, Oyo State, Nigeria)
Scientific Programme

Advancing towards TB elimination - significant contribution by rural health care providers (RHCPs) to national TB program using mobile technology in Tribal District of India
Archana Trivedi (USEA The Union, Delhi, India)

A pilot study to evaluate the experiences of TB patients when accessing TB services in five health facilities in Kisumu - Kenya
Edgar Makona (KELIN, Kenya)

Treatment adherence among TB patients in the private sector - combination of technology and human touch
Rishabh Chopra (PATH, India)

Tuberculosis eCurriculum series: a web-based self-paced education program
Zelalem Temesgen (Mayo Clinic, Minnesota, United States)

Ehlwoza
Anastasia Koch (University of Cape Town, Western Cape, South Africa)

Beyond the lab and behind the lens: an exploration of a community engagement initiative and its reflection of the lived experience of TB in Khayelitsha
Bianca Masuku (University of Cape Town, Western Cape, South Africa)

Disease surveillance through mobile phones: Geotagging the 'smart-phone' way
Rishabh Chopra (PATH, India)

Poster Exhibition
13:00 - 14:00
Poster Room

Translational Research

Lung tissue resident T cell immune responses to Mycobacterium tuberculosis infection in humans
Paul Ogongo (Kwa-Zulu Natal Research Institute for TB and HIV, South Africa)

Oral Presentation Posters: Transmission and Diagnosis

Deterministic linkage to evaluate the burden of recurrent TB disease in Cape Town, South Africa
Sabine Hermans (Desmond Tutu HIV Centre, Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa)

Mycobacterium tuberculosis molecular screening assay with sensitivity equivalent to culture
Sally McFall (Northwestern University, Illinois, United States)

Diagnostic accuracy of Xpert®MTB/Rif, experience at district hospital of Buenos Aires for tuberculosis diagnosis
Omar Sued (Hospital J. A. Fernandez, Buenos Aires, Argentina)
Development of a multi-analyte panel for non-invasive pharmacokinetic monitoring of second-line anti-tuberculosis drugs in small hair samples
John Metcalfe (University of California San Francisco (UCSF), United States)

Poster Exhibition
13:00 - 14:00
Poster Room

Oral Presentation Posters: Paediatric MDR TB and Clinical Epidemiology

- Treatment of multidrug-resistant tuberculosis (MDR-TB) in children and adolescents with a 9-month regimen in Africa
  Bassirou Souleymane (Action Damien Niger, Niger)
- Safety and tolerability of levofloxacin in HIV-infected and -uninfected children treated for multidrug-resistant tuberculosis
  Anthony Garcia-Prats (Stellenbosch University, South Africa)
- Spatio-temporal clustering of drug-resistant tuberculosis in KwaZulu-Natal, South Africa 2004-2010
  Allison Wolf (Columbia University, New York, United States)
- Diabetes and tuberculosis in Korean men and women: impact on tuberculosis incidence, recurrence and mortality
  Jonathan Golub (Johns Hopkins School of Medicine, Maryland, United States)

Poster Exhibition
13:00 - 14:00
Poster Room

Oral Presentation Posters: Community Engagement and Innovations

- Integrating HIV and TB interventions in the community to increase TB and HIV case detection, treatment adherence and TB treatment completion in Malawi and Zimbabwe
  Sameer Sah (TB Alert, United Kingdom)
- Anticorruption actions of patients of Ukraine increase access to TB treatment for additionally more than 28 000 patients in 2016
  Olha Stefanyshyna (CF 'Patients of Ukraine', Ukraine)
- Social support to TB patients by forming self help group (SHG) and facilitating skill development for sustainable livelihoods
  Archana Trivedi (USEA The Union, Delhi, India)
- Community advisory boards on repeat: what’s missing from TB clinical trials protocols
  Lindsay McKenna (Treatment Action Group, New York, United States)

Plenary Session
14:00 - 14:30
Session Room 12

Key Note Speech

Chairs:
Owen Ryan (International AIDS Society)
Keynote speech: TB and HIV: A call to action  
Stephen Lewis (co-director, AIDS-Free World)

Plenary Session  
14:45 - 16:00  
Session Room 12

**BS9, Breakout Session 9: Diagnostics and Biomarkers**

**Chairs:**
Robert Wallis (The Aurum Institute)  
Graeme Meintjes (University of Cape Town)

- **Lessons from the rollout of Xpert MTB/RIF in South Africa**  
  Wendy Stevens (NHLS, Johannesburg)  
  14:45

- **RePORT International: Advancing TB Research Using a Common Platform across Global Networks**  
  Carol Dukes Hamilton (Duke University & fhi360)  
  15:00

- **Novel biomarkers for monitoring treatment response**  
  Gerhard Walzl (Stellenbosch University)  
  15:15

- **Biomarkers with diagnostic accuracy in persons suspected for active TB**  
  Jayne Sutherland (MRC, Gambia)  
  15:30

- **Questions and Answers**  
  15:45

Parallel Session  
14:45 - 16:00  
Session Room 10

**Parallel Session 5 (Abstracts): Community Engagement and Innovations**

**Chairs:**
Erica Lessem (TAG)  
Lucia Ditli (Stop TB)

- **Community advisory boards on repeat: what’s missing from TB clinical trials protocols**  
  Lindsay McKenna (Treatment Action Group, New York, United States)  
  14:45

- **Social support to TB patients by forming self help group (SHG) and facilitating skill development for sustainable livelihoods**  
  Archana Trivedi (USEA The Union, Delhi, India)  
  15:00

- **Integrating HIV and TB interventions in the community to increase TB and HIV case detection, treatment adherence and TB treatment completion in Malawi and Zimbabwe**  
  Sameer Sah (TB Alert, United Kingdom)  
  15:15

- **Anticorruption actions of patients of Ukraine increase access to TB treatment for additionally more than 28 000 patients in 2016**  
  Olha Stefanyshyna (CF 'Patients of Ukraine', Ukraine)  
  15:30
Plenary Session
16:15 - 17:45

Session Room 12

CS, Closing Session: Next Steps and Call to Action

Chairs:
Haileyesus Getahun (WHO)

Closing key note speech 16:15
Trevor Mundel (Bill & Melinda Gates Foundation)

Panel discussion: Leadership in the fight to end TB 16:45
Moderator: Lucica Ditiu, Stop TB (Panelists: Parliamentarian Representatives from the African TB Caucus)